Objective To investigate the in vitro and in vivo anticancer effects of Usnea Diffracta Vain bioactive fraction AMH-T on human urogenital cancers, to observe the in vitro combination anticancer effects of AMH-T with cisplatin (DDP) and the physical toxicity of AMH-T, and to discuss the related mechanisms.
Methods MTT assay was used to measure the in vitro anticancer activity. The in vivo anticancer effects on HeLa tumor were tested in xenograft cancer model in balb/c nude mice. Mice body weight and organ coefficients were measured. Caspase-8 activity was detected by kit.
Results Cancer cells, ACHN, PC-3, T-24 and HeLa, died increasingly with the increasing AMH-T concentration and time. Cancer cells almost completely died at 8μg/ml of AMH-T after 72h. AMH-T and DDP showed synergistic in vitro anticancer effect on cancer cells. Treated with 50mg/kg of AMH-T, the relative proliferation ratio of HeLa tumor was 23.67% and the weight inhibitory ratio was 54.20%. No significant difference was found in organ coefficients of spleen, kidney, heart and testis except liver. Caspase-8 activity was not affected by AMH-T.
Conclusion AMH-T has significant in vitro and in vivo anticancer effects on human urogenital cancers. AMH-T and DDP have synergistic in vitro anticancer effects. The apoptosis induced by AMH-T has no relationship with Caspase-8 signaling pathway.
DownLoad: